Finoriq research workspace
Alzamend Neuro, Inc. (ALZN) News
Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline. Review ALZN recent headlines, source links, and company news on Finoriq.
Company Snapshot
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
- Company
- Alzamend Neuro, Inc. (ALZN)
- Ticker
- ALZN
- Market Cap
- $4.8M
- Latest Price
- $1.26
- Industry
- Biotech & Pharma
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.